Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man  by Hollman, Peter C.H et al.
FEBS Letters 418 (1997) 152-156 FEBS 19518 
Relative bioavailability of the antioxidant navonoid quercetin from 
various foods in man 
Peter C.H. Hollmana'*, John M.P. van Trijpa, Michel N.C.P. Buysmana, 
Martijn S. v.d. Gaagb, Marcel J.B. Mengelersa, Jeanne H.M. de Vriesb, Martijn B. Katanb 
aDLO-State Institute for Quality Control of Agricultural Products (RIKILT-DLO), Bornsesteeg 45, 6708 PD Wageningen, The Netherlands 
bDivision of Human Nutrition and Epidemiology, Agricultural University, Wageningen, The Netherlands 
Received 15 September 1997; revised version received 16 October 1997 
Abstract Quercetin is a strong antioxidant and a major dietary 
flavonoid. Epidemiological studies suggest that consumption of 
quercetin protects against cardiovascular disease, but its 
absorption in man is controversial. We fed nine subjects a single 
large dose of onions, which contain glucose conjugates of 
quercetin, apples, which contain both glucose and non-glucose 
quercetin glycosides, or pure quercetin-3-rutinoside, the major 
quercetin glycoside in tea. Plasma levels were then measured over 
36 h. Bioavailability of quercetin from apples and of pure 
quercetin rutinoside was both 30% relative to onions. Peak levels 
were achieved less than 0.7 h after ingestion of onions, 2.5 h after 
apples and 9 h after the rutinoside. Half-lives of elimination were 
28 h for onions and 23 h for apples. We conclude that conjugation 
with glucose enhances absorption from the small gut. Because of 
the long half-lives of elimination, repeated consumption of 
quercetin-containing foods will cause accumulation of quercetin 
in blood. 
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pounds, which are called glycosides in general, or more spe-
cifically glucosides, rutinosides, or xylosides depending on 
their sugar moiety. The sugar-flavonol bond is a (3-glycosidic 
bond which is resistant to hydrolysis by pancreatic enzymes. It 
was thought that such glycosides cannot be absorbed [1]. 
However, when we measured faecal quercetin in ileostomy 
subjects we found that human absorption of quercetin-p-glu-
cosides from onions was 52%, whereas absorption of querce-
tin without its sugar moiety, the so-called aglycone, and of 
quercetin-|3-rutinoside were both only about 20% [12]. These 
data suggest that the sugar moiety of quercetin glycosides 
affects their absorption. In the present study we determined 
the bioavailability and other pharmacokinetic parameters of 
various quercetin glycosides contained in foods. Subjects in-
gested onions, apples and pure quercetin rutinoside (rutin), 
the major quercetin compound found in tea [13]. Onions con-
tain mainly glucose glycosides of quercetin [14,15]. Apples 
contain a variety of quercetin glycosides, including galacto-
sides, arabinosides, rhamnosides, xylosides, and glucosides 
(Fig. 1) [16-18]. Preliminary pharmacokinetic data on onions 
have been published [19]. 
1. Introduction 
Flavonoids are polyphenolic compounds that occur ubiqui-
tously in foods of plant origin [1]. Quercetin is the major 
representative of the flavonoid subclass of flavonols [2]. Quer-
cetin is a strong antioxidant because it can chelate metals, 
scavenge oxygen free radicals [3,4] and prevent the oxidation 
of low density lipoprotein (LDL) in vitro [5]. Oxidized LDL is 
hypothesized to be an intermediate in the formation of athe-
rosclerotic plaques [6]. Quercetin might therefore contribute 
to the prevention of atherosclerosis [7]. Indeed, the intake of 
flavonols was inversely associated with subsequent cardiovas-
cular disease in several though not all prospective epidemio-
logical studies [8]. 
An evaluation of the role of dietary quercetin as a protec-
tive antioxidant in man is hampered by uncertainties about its 
absorption. Pharmacokinetic data are scarce and contradic-
tory [9,10]. Until now, determination of the bioavailability 
of quercetin from real foods was not possible, because ana-
lytical methods for the determination of quercetin in plasma 
lacked sensitivity. We have recently developed a specific and 
sensitive detection technique for quercetin in plasma which 
allows studies on its bioavailability from foods [11]. 
Flavonols are present in foods as flavonoid-sugar com-
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2. Materials and methods 
2.1. Subjects 
We recruited five women and four men, with a mean age of 24.8 
(range 2CM7) years. All were healthy based on a medical question-
naire and routine hematological and biochemical measurements in 
blood and urine. Subjects did not use any medication. The protocol 
was approved by the Wageningen University Ethical Committee, and 
was fully explained to the participants, who gave their written in-
formed consent. 
2.2. Study design, foods, and supplements 
Subjects followed a quercetin-free diet [12] during three experimen-
tal periods each of 5 days. These periods were separated by 9 days 
without treatment and without a prescribed diet. On day 4 of each 
experimental period we provided one out of three different quercetin-
containing supplements in random order, namely fried onions, apples, 
and rutinoside. Supplements were given at breakfast; blood was col-
lected periodically over the next 36 h and urine continuously for 24 h. 
The onions provided 225 ±43 (S.D.) umol (68 ±13 mg quercetin 
equivalents) and the apple supplement, consisting of applesauce plus 
apple peel, provided 325 ± 7 umol of quercetin. For the third treat-
ment 331 umol quercetin-3-O-P-rutinoside (Rutosidum DAB, 
#339994; OPG Farma, Utrecht, The Netherlands) was administered 
in a capsule. The breakfasts which were given together with these 
supplements have been described previously [12]. Subjects also took 
a capsule containing 80 mg para-aminobenzoic acid (#361334; OPG 
Farma) as a recovery marker for urine [20] at breakfast, lunch and 
dinner. Subjects were instructed not to eat anything and to drink only 
water or coffee without milk from after the experimental breakfasts 
until lunch. 
Average energy intake on day 3 of each period according to 24-h 
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Fig. 1. Structure of quercetin aglycone (I), quercetin glucoside (II) 
as present in onions, quercetin galactoside (III) as present in apples, 
and quercetin rutinoside or rutin (IV). 
dietary recalls [21] was 10.4 ±1.5 MJ, of which protein provided 
13.2±1.8% of energy, fat 33.9±5.4%, and carbohydrates 
52.5 ± 5.7%, with no differences between treatment periods. 
2.3. Collection of samples 
Venous blood samples were taken into vacuum tubes containing 
EDTA; zero time was 10 min after the start of the breakfast. Plate-
let-rich plasma was prepared within 15 min by centrifugation at 20°C 
for 10 min at 200Xg; it was stored at —80°C until analysis. 
Subjects collected urine in plastic bottles containing 0.13 g thymol 
(#8167; Merck) for 24 h after each supplemented breakfast and 
stored them in dry ice immediately after voiding. Upon arrival at 
the laboratory, urine samples were thawed in a water bath at 40°C, 
homogenized and pooled per subject and per treatment day. Aliquots 
were taken within 30 min, frozen, and stored at —40°C until analyzed. 
2.4. Analytical methods 
Quercetin, quercetin glycosides, glucuronides, and sulfates were ex-
tracted from plasma or urine and hydrolyzed to the aglycone form in 
2 M HC1 in aqueous methanol [19]. For plasma we extended the 
hydrolysis period to 5 h. For urine 15.0 ml methanol containing 2 g 
tert-buty\ hydroxyquinone/1 and 5 ml 10 M HC1 were added to 5 g 
urine followed by mixing. The mixture was refluxed at 90°C for 
8 hours with regular swirling, allowed to cool, subsequently brought 
to a final volume of 50 ml with methanol, and sonicated for 5 min. 
For HPLC analysis we transferred 1.5 ml of the plasma or urine 
extract into an HPLC vial and added 15 ul 100 g/1 ascorbic acid. We 
injected 20 ul onto a reversed-phase C18 column connected to a post-
column reaction coil, where quercetin was transformed into a fluores-
cent quercetm-aluminum complex [11,19]. Peak identity was con-
firmed by comparing the retention time of the plasma quercetin 
peak with that of a standard quercetin. Potential co-elution of fluo-
rescent non-flavonol compounds was checked by repeating the HPLC 
procedure, this time by omitting the aluminum. Such compounds were 
never observed. 
The limit of detection was 0.007 uM (2 ng/ml) for plasma and 0.01 
uM (3 ng/ml) for urine. Recovery of 0.33 nmol (100 ng) quercetin 
aglycone added to 1 ml plasma was 88 ± 3% (6 additions). Addition of 
0.83 nmol (250 ng) quercetin aglycone per gram of urine yielded a 
recovery of 99 ± 7% (3 additions). 
The relative standard deviation of duplicates was 4% for plasma 
and 6% for urine. We included a control sample of plasma and urine 
in each series of analyses; all values were within 0.23 ±0.046 uM 
(mean ± 2 S.D., 15 single determinations) for plasma and within 
3.02 ± 0.55 uM (mean ± 2 S.D., 15 duplicate determinations) for urine. 
/>ara-Aminobenzoic acid in urine was determined as described [22]. 
2.5. Data analysis 
We used the two-compartment open model C(t) = — Ce - k t +Ae _ a t + 
Be^P* to describe the absorption and disposition, i.e. distribution, 
metabolism and elimination, of quercetin [23] using PCNONLIN ver-
sion 4.0 (SCI Software, ClinTrials Inc., Lexington, KY, USA). 
Values were normalized by conversion to logio values for statistical 
testing. Analysis of variance (SPSS Inc., Chicago, IL, USA) was per-
formed with subject, type of quercetin source, and type of quercetin 
source in preceding period as independent variables. The significance 
of differences was determined by paired Mest. No significant relation 
Table 1 
Kinetic parameters of quercetin absorption and disposition in nine subjects after one-time ingestion of fried onions, apples, or pure quercetin 
rutinoside 
Parameter Supplement 
Onions Apples Rutinoside 
Absorption 
time to reach peak level (h) 
peak level (uM) 
peak level (ng/ml) 
Distribution half-life (h) 
Elimination half-life (h) 
AUCo^oo (h-ng/ml) 
AUC0^36h (h-ng/ml) 
0.70±1.08a 
0.74 ± 0.15a 
224±44a 
4.4 ±4.3 
28 ±92 
2974 ±2315 
2330±849a 
2.51±0.72b 
0.30±0.06b 
92+19b 
2.4 ±3.7 
23 ±32 
1334 ±465 
1061±375b 
9.3±1.8C 
0.30±0.30b 
90±93 b 
983±978b 
Each subject received each supplement in random order at 14-day intervals. 
Data are means ± S.D. for nine subjects. 
a,bcResults with a different superscript letter differ significantly (P<0.001). 
- , not calculated because of too few data points. 
AUCo->», total area under the plasma concentration-time curve; AUCo^36h, area under the plasma concentration-time curve over the first 36 h. 
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with individual subject or with supplement given in the preceding 
period was found. 
We calculated the relative bioavailability by comparing the areas 
under the plasma concentration-time curve (AUC) up to 36 h (Table 1) 
after correction for dosage. 
3. Results 
3.1. Plasma concentration of quercetin 
Intake of onions and apples led to a rapid rise, and of the 
rutinoside (rutin) to a very slow rise of quercetin levels in 
plasma. The area under the plasma concentration-time curve 
(AUC), the quercetin peak plasma level, and the time to reach 
the peak plasma level differed markedly between supplements 
(Table 1). 
The mean peak level was 0.74 uM (224 ng/ml) after onions, 
0.30 uM (92 ng/ml) after apples, and 0.30 uM (90 ng/ml) after 
quercetin-3-rutinoside. Peak levels were reached 0.7 h after 
ingestion of the onions, 2.5 h after the apples, and 9 h after 
the quercetin-3-rutinoside (Fig. 2, Table 1). In four out of 
nine subjects the quercetin concentration had reached its max-
imum observed concentration already at 0.5 h after the onions 
supplement, the first data point after consumption of the sup-
plement. Therefore, the time needed to reach the peak level 
may have been overestimated, and the height of the peak 
underestimated. 
Distribution, metabolism and elimination of quercetin in 
plasma after the onions and apples supplements was best de-
scribed by a two-compartment model (Fig. 2). Data analysis 
for quercetin-3-rutinoside escaped the model because the de-
layed absorption resulted in too few data points. The average 
half-lives of the distribution and elimination phases were not 
statistically different between onions and apples (Table 1). We 
could still detect quercetin 36 h after ingestion of the supple-
ments; at that time the mean plasma concentration was 
0.060 ± 0.027 uM after onions, 0.030 ± 0.030 uM after apples, 
and 0.027 ±0.023 uM after quercetin-3-rutinoside (Fig. 2). 
The bioavailability of quercetin from both apples and the 
rutinoside was 30% of that of quercetin from onions. 
3.2. Urinary excretion of quercetin 
Excretion of quercetin and its conjugates in urine after in-
gestion of the onions was 1.39% of the administered dose, 
whereas it was only 0.44% after the apples, and 0.35% after 
the rutinoside (Table 2). One subject (#3) excreted much more 
quercetin in urine after consumption of quercetin-3-rutinoside 
than did the other subjects (Fig. 3). Quercetin excretion of this 
subject after the rutinoside was only 30%> less than that after 
the onions, whereas all the other subjects excreted at least 80% 
less after the rutinoside than after the onions. 
Three of the subjects collected urine every few hours. They 
reached 90% of their cumulative 24 h urinary excretion of 
- - - o . o o 
30 36 
Time (hours) 
Fig. 2. Time course of the quercetin concentration in plasma of 
nine subjects after ingestion of fried onions, apples, or quercetin ru-
tinoside. Each subject received each supplement in random order at 
14-day intervals. Data are means ± S.E.M. for nine subjects. • , 
onions; o> apples; ▲, rutinoside. 
quercetin within 8-13 h with all supplements. This suggests 
that urinary excretion of quercetin is almost complete after 
24 h. 
For all three supplements, the area under the plasma con-
centration-time curve correlated highly with 24-h urinary ex-
cretion of quercetin per subject (Fig. 3). 
3.3. Compliance with the quercetin-free diet 
The average intake of quercetin from regular foods accord-
ing to 24-h dietary recalls on the third day of each of the three 
diet periods was 5 ± 3 |o.mol (1.5±0.9 mg). No difference in 
quercetin intake from the background diet was observed be-
tween the three diet periods. Plasma quercetin concentration 
before breakfast was on average 0.017 ±0.013 |iM. Thus, 
compliance with the quercetin-free diet was excellent. 
3.4. Completeness of collection of urine 
Urinary recovery of />ara-aminobenzoic acid was 
87.3 ± 10.0%, indicating acceptable compliance in collecting 
urine [20]. On six out of 27 person-days subjects reported 
not to have swallowed the />ara-aminobenzoic acid capsule 
at dinner, so compliance of these subjects at evening could 
not be checked. As quercetin was almost completely excreted 
in urine within the first 10 h after the supplemented break-
fasts, this uncertainty is of minor importance. 
4. Discussion 
Our data show that the dietary antioxidant quercetin is 
found in the circulation after consumption of major dietary 
sources of quercetin. Bioavailability and absorption kinetics 
Table 2 
Intake of quercetin at breakfast and subsequent mean cumulative excretion of quercetin in urine over 24 h 
Supplement (to breakfast) 
Onions 
Apples 
Rutinoside 
Quercetin intake (umol) 
225 ±43 
325 ±7 
331 ±7 
Quercetin excretion in 
Amount (umol) 
3.22 ±1.60 
1.45 ±0.71 
1.17± 1.34 
urine 
Proportion of intake (%) 
1.39±0.49a 
0.44±0.22b 
0.35±0.41b 
Each of the nine subjects received each supplement in random order at 14-day intervals. 
Data are means ± S.D. for nine subjects. 
a,bResults with a different superscript letter differ significantly (P< 0.001). 
P.C.H. Hollman et al.lFEBS Letters 418 (1997) 152-156 155 
^ 6000 
1 
£? 5000 -
O 4000 - • 
ID 
< . AJ3 
.E 3000 -
0 
® 2000 - w ,-Q 
| ^ -q^ ° 
0.0 0.5 1.0 1.5 2.0 2.5 
Quercetin in urine(% of oral dose) 
Fig. 3. Correlation between the area under the concentration-time 
curve (AUC) of quercetin in plasma and the 24-h excretion in urine 
of nine subjects who consumed onions, apples or quercetin rutino-
side. The area was standardized to an intake of 331 umol quercetin 
glycosides; urinary excretion is expressed as a percentage of the in-
gested dose. Each subject received each supplement in random order 
at 14-day intervals. Values are means for nine subjects for each sup-
plement. The correlation coefficient (r) was 0.93 for 27 data points. 
• , onions; o, apples; A, rutinoside. 
differed widely between sources. A major difference between 
these sources is the type of glycoside. Quercetin from onions, 
which contain only glucosides, was rapidly absorbed, whereas 
pure quercetin-3-rutinoside, the major species in tea, showed a 
markedly delayed absorption. The absorption rate from ap-
ples, which contain a variety of glycosides, was intermediate. 
Thus, these results point to a predominant role of the sugar 
moiety in the bioavailability and absorption of dietary quer-
cetin in the human body. However, it cannot be ruled out that 
differences between apples and onions in cell wall structures, 
location of glycosides in cells, or their binding to cell constit-
uents also affect the liberation of quercetin from these foods 
in the gastrointestinal tract. 
4.1. Pharmacokinetics 
The biphasic concentration profile in the elimination of 
quercetin from plasma (Fig. 2) indicates a rather fast distri-
bution and elimination followed by a slow final elimination. 
Because most of the urinary quercetin is excreted within the 
first 12 h, urinary excretion contributes to this first rather fast 
decrease, and is only of minor importance in the second final 
phase. We only can speculate on the elimination mechanisms 
in the final phase. Biliary recirculation, as described in rats 
[24], offers a possible explanation: quercetin eliminated in the 
first fast phase may be reabsorbed in the colon thus slowing 
down elimination. It also possible that quercetin slowly pen-
etrates into tissues where it is subsequently metabolized into 
compounds that escape our assay. However, conjugates with 
various pharmacokinetic properties formed upon or after ab-
sorption also may cause such a biphasic profile. 
After consumption of a single portion of onions and apples, 
a considerable fraction of the absorbed quercetin was present 
in plasma throughout the day as is indicated by the elimina-
tion half-lives of about 24 h. The plasma time curve after 
consumption of the rutinoside indicates a similar slow elimi-
nation. A more accurate estimation of half-lives would require 
plasma samples to be taken for 3 days. The long half-lives 
implicate that repeated intake of onions, apples, and possibly 
tea would lead to a build-up of quercetin in plasma. The 
different rates of absorption of quercetin measured after in-
gestion of the various supplements will cause quercetin to 
enter the plasma continuously for a few hours following a 
mixed meal containing a variety of quercetin sources. We ear-
lier found a peak plasma concentration of 0.75 uM or 225 ng/ 
ml after administration of a single high dose of dietary quer-
cetin equivalent to 4 times the average Dutch daily intake [2]. 
Concentrations of the dietary antioxidant p-carotene in hu-
man plasma are similar to this value [25]. Thus in subjects 
who regularly eat onions, plasma quercetin levels may ap-
proach those of |3-carotene. 
24-h Urinary excretion of quercetin predicted the area 
under the plasma concentration-time curve (AUCo^36h) very 
well (Fig. 3). Thus, the bioavailability of quercetin from foods 
can be predicted from its 24-h excretion in urine, which ob-
viates the need for repeated blood sampling. 
Our quercetin assay in plasma and urine measured the sum 
of free quercetin, quercetin glycosides, and any glucuronides 
and sulfates formed by conjugation in the liver or the small 
intestine [26]. Methylated quercetin formed in the liver [24] 
escaped our assay, because it would not be hydrolyzed. Quer-
cetin glucuronides, sulfates and glycosides, if present in plas-
ma, might each show a somewhat different distribution and 
elimination. In addition, for apples each separate glycoside 
probably is absorbed at its own rate. Thus, the pharmacoki-
netic parameters calculated reflect the summed absorption and 
disposition of various conjugates. 
4.2. Comparison with previous studies 
Absorption profiles of fiavonols in plasma were determined 
in two subjects by Nieder [10] after administration of an un-
specified type and amount of flavonol glycosides from Ginkgo 
biloba. Peak concentrations of fiavonols in plasma were 
reached after 2-2.5 h. Quercetin glycosides were detected in 
plasma of two unsupplemented volunteers [27]. Quercetin 
aglycone could not be detected in plasma of human subjects 
by Gugler et al. [9] after oral administration of even 4 g of 
quercetin aglycone. However, their assay, which had a limit of 
detection of 0.33 |xM (100 ng/ml), would not have detected 
quercetin present as conjugates. The elimination half-lives of 
2-4 h measured by Nieder [10] after oral, and Gugler et al. [9] 
after intravenous administration were much shorter than 
those reported here, possibly because in both studies the plas-
ma concentration was not measured for long enough. Most 
likely these authors mistook the distribution phase for the 
elimination phase. 
4.3. Mechanisms of absorption 
The short time to reach peak levels after onion glucosides 
points to absorption from the stomach or small intestine, 
whereas the prolonged time needed for the rutinoside to reach 
its peak suggests that it transits the small intestine and is 
absorbed from the colon. We previously showed that intact 
glucosides are absorbed well [12]. The presence of quercetin 
glycosides in human plasma [27] suggests that intact glyco-
sides may be absorbed. However, hydrolysis of the rutinoside 
may be necessary before absorption can occur. Because the 
rutinoside is a P-glycoside, only microorganisms in the colon 
can mediate hydrolysis, but at the same time they will also 
degrade the liberated aglycone [1]. In contrast with the present 
study in volunteers with a complete gastro-intestinal tract, we 
found practically no urinary excretion of quercetin or its con-
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jugates after administration of the rutinoside to ileostomy 
subjects, who lack a colon [12]. This again provides evidence 
for a role of the colon in the absorption of quercetin rutino-
side, the major species in tea. The present study suggests that 
the sugar moiety has a predominant effect on the absorption 
and plasma levels of quercetin. 
We found that quercetin glycosides present in major food 
sources of flavonols are absorbed, and that they are elimi-
nated slowly throughout the day. Quercetin could thus con-
tribute significantly to the antioxidant defences present in 
blood plasma. 
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